New Compounds Protect Nervous System from Structural Damage of MS
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai. "The compounds identified in this study, when administered orally, both reduced the inflammation that is a hallmark of multiple sclerosis and protected against the nerve cell damage seen in mouse models of the disease," said Jeffery Haines, PhD, a post-doctoral fellow at Mount Sinai and the study's lead author. "The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders," says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.
- Dr. Patrizia Casaccia, Professor, Neuroscience, Genetics and Genomic Science, Neurology, Icahn School of Medicine at Mount Sinai, Chief, the Center of Excellen for Myelin Repair, the Friedman Brain Institute at Mount Sinai
- Jeffrey Haines, PhD, Postdoctoral Fellow, Neuroscience, Icahn School of Medicine at Mount Sinai